The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.

Company Guidance

During AbbVie's Second Quarter 2025 Earnings Conference Call, the company reported adjusted earnings per share of $2.97, exceeding the guidance midpoint by $0.11. Total net revenues for the quarter were $15.4 billion, surpassing expectations by over $400 million, with significant contributions from Skyrizi and Rinvoq, which together are projected to achieve more than $25 billion in sales this year. The company raised its full-year revenue guidance by $800 million to $60.5 billion and increased its full-year adjusted earnings per share guidance by $0.21 to a range of $11.88 to $12.08. AbbVie highlighted strong double-digit growth in neuroscience and noted progress in its R&D pipeline, including several late-stage program approvals and strategic acquisitions to bolster its future growth.

Strong Financial Performance

Adjusted earnings per share of $2.97, $0.11 above guidance midpoint. Total net revenues were $15.4 billion, exceeding expectations by over $400 million.

Robust Growth in Key Segments

Sales growth of 22% from the ex-HUMIRA platform, with Skyrizi and Rinvoq expected to deliver more than $25 billion in combined sales this year. Neuroscience segment also showed strong double-digit growth driven by Vraylar, Vyalev, and migraine portfolio.

Increased Guidance

Full-year revenue guidance raised by $1.5 billion since the start of the year, now expecting $60.5 billion. Adjusted EPS guidance increased to between $11.88 and $12.08.

Pipeline Advancements

Notable approvals for EMRELIS in non-small cell lung cancer and Rinvoq for GCA. Regulatory submission for TrenibotE in aesthetics and positive Phase III results in alopecia areata.

Strategic Acquisitions and Collaborations

Over 30 business development transactions since last year, including acquisition of Capstan Therapeutics and collaboration with ADARx for siRNA therapies.

AbbVie (DE:4AB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:4AB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	2.79 / -	2.565	―	―	―
Jul 31, 2025	2025 (Q2)	2.46 / 2.54	2.266	12.08% (+0.27)	―
Apr 25, 2025	2025 (Q1)	2.03 / 2.10	1.975	6.49% (+0.13)	―
Jan 31, 2025	2024 (Q4)	1.81 / 1.85	2.385	-22.58% (-0.54)	―
Oct 30, 2024	2024 (Q3)	2.50 / 2.56	2.522	1.69% (+0.04)	―
Jul 25, 2024	2024 (Q2)	2.19 / 2.27	2.488	-8.93% (-0.22)	―
Apr 26, 2024	2024 (Q1)	1.93 / 1.98	2.103	-6.10% (-0.13)	―
Feb 02, 2024	2023 (Q4)	2.39 / 2.39	3.078	-22.50% (-0.69)
Oct 27, 2023	2023 (Q3)	2.45 / 2.52	3.129	-19.40% (-0.61)	―
Jul 27, 2023	2023 (Q2)	2.42 / 2.49	2.881	-13.65% (-0.39)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:4AB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	€166.20	€170.00	+2.29%
Apr 25, 2025	€157.03	€159.81	+1.77%
Jan 31, 2025	€165.61	€177.59	+7.24%
Oct 30, 2024	€170.81	€177.76	+4.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.